Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)
2018 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)
Ottmann, O. G.; Pfeifer, H.; Cayuela, J.-M.; Spiekermann, K.; Jung, W. ; Beck, J. & Raffoux, E. et al. (2018)
Blood, 132(Supplement 1) pp. 31-31. DOI: https://doi.org/10.1182/blood-2018-99-114552
Documents & Media
Details
- Authors
- Ottmann, Oliver G.; Pfeifer, Heike; Cayuela, Jean-Michel; Spiekermann, Karsten; Jung, Wolfram ; Beck, Joachim; Raffoux, Emmanuel; Turlure, Pascal; Himberlin, Chantal; Huguet, Francoise; Viardot, Andreas; Wendelin, Knut; Reichle, Albrecht; Maury, Sébastien; Sanhes, Laurence; Isnard, Francoise; Cahn, Jean-Yves; Lepretre, Stephane; Chevallier, Patrice; Escoffre-Barbe, Martine; Ribera, Josep-Maria; Hoelzer, Dieter; Goekbuget, Nicola; Dombret, Hervé; Rousselot, Philippe
- Issue Date
- 2018
- Journal
- Blood
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
